The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $147,656 Project Grant to Beth Israel Deaconess Medical Center, Inc. (Bidmc) to study the impact of APOL1 copy number variations on kidney disease susceptibility in African Americans. The 2.5-year grant, which began on January 11, 2025, will fund research to characterize the risk variant architecture of APOL1 copy number variations and determine the functional consequences of harboring these variations. The...
This Project Grant award, valued at $491,366, was issued by the National Human Genome Research Institute (NHGRI) under the Human Genome Research federal grant program (CFDA 93.172). The award is focused on developing new algorithms to robustly map disease-associated genetic variants to critical target genes, particularly in underrepresented populations. Key objectives include: Improving the ability to identify disease-critical genes in non-European populations where data is limited. Developing...
This Project Grant award from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), aims to develop new methods to predict disease risk among individuals with rare monogenic risk alleles. The $1,100,866 award will fund research at the Icahn School of Medicine at Mount Sinai to leverage deep learning techniques on Electronic Health Records, metabolomics, and proteomics data from sources like the UK Biobank and NIH All of Us program. The...
This Project Grant award, with the ID R01HG013163, was provided by the National Human Genome Research Institute (NHGRI) under the Human Genome Research federal grant program (CFDA 93.172). The $1,604,308.15 award supports a multi-omics study of ancestry-enriched associations in Hispanic/Latino populations, which aims to leverage genomic and multi-omics data to map genomic segments and variants inherited from ancestral populations and assess their relationship to disease states. The key...
The federal Project Grant award R01DK140129, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research to optimize the allocation of kidneys from deceased African American donors with APOL1 high-risk genotypes. The primary goal is to identify clinically actionable approaches to determine which of these kidneys are truly "high risk" for...
This Project Grant award from the National Human Genome Research Institute (NHGRI), under the federal Human Genome Research grant program (CFDA 93.172), is focused on enhancing the interpretability and applicability of polygenic scores through the integration of multi-omics data and family-based studies. The primary objectives are to: 1) develop machine learning approaches to integrate genetic, multi-omics, and environmental data to construct partitioned polygenic scores representing distinct...
The National Human Genome Research Institute (NHGRI) awarded a $1,033,069.24 Project Grant (CFDA 93.172 - Human Genome Research) to The Johns Hopkins University to develop novel statistical methods for data integration and applications to genome-wide association studies (GWAS). The 4-year project, running from September 2024 to June 2028, will focus on three key aims: Developing a framework for building generalized linear models using detailed covariate data from a main study while incorporating...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $252,000.00 to investigate the effect of ubiquitin D variants on kidney injury mediated by APOL1 in persons with HIV. The research aims to determine how genetic variants of ubiquitin D interact with APOL1 risk alleles to promote podocyte injury and increase the risk of...
This federal Project Grant award of $423,750.00 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research by New York University School of Medicine to deepen understanding of the genetic basis of complex human traits and diseases. The key objectives are to: 1) identify the most important genes contributing to complex traits, 2) characterize gene-gene and gene-environment interactions, and 3) develop...
This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) is focused on developing and applying machine learning-based approaches to estimate disease risk in diverse and admixed populations. The $399,156 award to Galatea Bio Inc., a minority-owned small disadvantaged business located in Miami Lakes, FL, will support the following key objectives over the project period from September 2024 to August 2025: Evaluating the performance of existing...
This federal Project Grant award R21HG013814 was provided by the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172) to Case Western Reserve University. The $874,886 grant, awarded on September 9, 2024, aims to use the APOL1 gene as a model to quantify and identify environmental modifiers of genetic associations in diverse populations. The research will access data from the NEPTUNE, UK Biobank, and All of Us datasets to examine how APOL1 genetic risk for rare and common kidney outcomes is modified, including investigating the potential modifying effects of heavy metal exposure. The research will provide data to develop at-risk profiles for APOL1 variant carriers and identify targets for prevention and therapeutic development. The project period runs through July 31, 2025.